Clinical trial NCT02250378: Stereotactic Radiosurgery Followed by Wedge Resection in Treating Patients With Early Stage Peripheral Non-small Cell Lung Cancer
Official title: Feasibility Study of Stereotactic Body Radiation Therapy Followed by Wedge Resection for Peripherally Located Early Stage Non-small Cell Lung Cancer
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: NA
Conditions: Recurrent Non-small Cell Lung Cancer
Stage IA Non-small Cell Lung Cancer
Stage IB Non-small Cell Lung Cancer
Lead sponsor: University of Southern California
Sponsor class: OTHER
Collaborators: name: National Cancer Institute (NCI)
First posted: 2014-09-26
Enrollment: 0
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This pilot clinical trial studies the side effects and how well stereotactic radiosurgery followed by wedge resection works in treating patients with early stage non-small cell lung cancer that is located in the outer, or peripheral, areas of the lung. Stereotactic radiosurgery, also known as stereotactic body radiation therapy, is a specialized radiation therapy that delivers a single, high dose of radiation directly to the tumor and may kill more tumor cells and cause less damage to normal tissue. Wedge resection is a less invasive type of surgery for removal of the tumor and a small amount of normal tissue around it. Giving stereotactic radiosurgery followed by wedge resection may be a safe treatment option for patients who cannot receive standard treatment with lobectomy.

Detailed description: PRIMARY OBJECTIVES:

I. To assess the safety and feasibility of a wedge resection following stereotactic body radiation therapy (SBRT) for early stage peripheral non-small cell lung cancer (NSCLC).

SECONDARY OBJECTIVES:

I. To assess pathologic response rates to SBRT as determined by pathologic examination of resected tumors.

II. To prospectively assess patient quality of life when treated with SBRT and wedge resection.

TERTIARY OBJECTIVES:

I. To describe the location of viable tumor and to correlate pathologic response rates with radiation dose, size of tumor, and tumor histology.

II. To correlate pathologic response rates and functional imaging with pre- and post-treatment dual-input perfusion (DP)-computed tomography (CT) and positron emission tomography (PET)-CT.

III. To correlate changes in serum levels of deoxyribonucleic acid (DNA) methylation and circulating tumor cells (CTC) with pathologic response rates.

OUTLINE:

Patients undergo stereotactic radiosurgery every other day for 3 or 5 fractions (depending on the size tumor and proximity to the chest wall). Within 4-6 weeks after completion of stereotactic radiosurgery, patients undergo wedge resection.

After completion of study treatment, patients are followed up at 1, 3, 6, and 12 months.

Eligibility criteria: Inclusion Criteria:

* Eastern Cooperative Oncology Group (ECOG) performance status 0, 1, or 2
* Biopsy proven non-small cell lung cancer
* Maximum tumor dimension =\< 5 cm
* No clinical evidence of N1, N2 or N3 lymph nodes as assessed by CT and/or PET-CT
* No evidence of distant metastatic disease
* Tumor verified by a thoracic surgeon to be in a location that will permit a sublobar resection
* Tumor located peripherally within the lung (peripheral defined as not touching any surface within 2 cm of the proximal bronchial tree in all directions) and not touching the mediastinal pleura
* Pulmonary function tests (PFTs) with diffusing capacity of the lung for carbon monoxide (DLCO) within 90 days prior to registration
* Patient at high-risk of complications from lobectomy meeting a minimum of one major criteria or two minor criteria as described below:

  * Major criteria

    * Predicted postoperative forced expiratory volume in one second (FEV1) =\< 40%
    * Predicted postoperative DLCO =\< 40%
    * Age \>= 72
  * Minor criteria

    * Predicted postoperative FEV1 41-60%
    * Predicted postoperative DLCO 41-60%
    * Pulmonary hypertension (defined by a pulmonary artery systolic pressure greater than 40 mm Hg) as estimated by echocardiography or right heart catheterization
    * Poor left ventricular function (defined as an ejection fraction 40% or less)
    * Resting or exercising arterial partial pressure of oxygen (pO2) =\< 55 mmHg or oxygen saturation (SpO2) =\< 88%
    * Partial pressure of carbon monoxide (pCO2) \> 45 mm Hg
    * Modified Medical Research Council Dyspnea Scale \>= 3
* Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and for 90 days following completion of therapy; should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately

  * A female of child-bearing potential is any woman (regardless of sexual orientation, having undergone a tubal ligation, or remaining celibate by choice) who meets the following criteria:

    * Has not undergone a hysterectomy or bilateral oophorectomy; or
    * Has not been naturally postmenopausal for at least 12 consecutive months (i.e., has had menses at any time in the preceding 12 consecutive months)
* Ability to understand and the willingness to sign a written informed consent

Exclusion Criteria:

* Pregnant women
* Patients with central tumors within the proximal tree or touching the mediastinal pleura
* Patients with evidence of distant metastatic disease

Primary outcomes:
measure: Rate of grade 3-5 adverse events, graded according to National Cancer Institute Common Terminology Criteria for Adverse Events version 4.03
timeFrame: Up to 12 months after surgery
measure: Rates of perioperative complications including blood loss, days in the intensive care unit, and operative time
timeFrame: Up to 12 months after surgery
measure: Feasibility, determined by the number of patients who are able to complete wedge resection as well as receive the full dose of stereotactic radiosurgery
timeFrame: Up to 12 months after surgery
Secondary outcomes:
measure: Pathologic response rates
timeFrame: Up to 12 months after surgery
measure: Quality of life assessment
timeFrame: Up to 12 months after surgery
Other outcomes:
measure: Imaging characteristics that may predict response based on DP-CT and PET-CT scans
timeFrame: Up to 30 days after stereotactic radiosurgery
measure: Changes in perfusion using DP-CT scans
timeFrame: Baseline to up to 30 days after stereotactic radiosurgery
measure: Changes in FDG uptake
timeFrame: Baseline to up to 12 months after surgery
measure: Changes in DNA methylation analysis
timeFrame: Baseline to up to 12 months after surgery
measure: Changes in CTC levels
timeFrame: Baseline to up to 12 months after surgery
Locations:
city: Los Angeles
country: United States
facility: USC Norris Comprehensive Cancer Center
state: California
Study officials:
affiliation: University of Southern California
name: Eugene Chung
role: PRINCIPAL_INVESTIGATOR
References: